Skip to content

A Retrospective Investigation on the Treatment of Acute Respiratory Tract Infections with the Combination of Traditional Chinese Medicine and Antiviral Agents

A large-sample observational cohort study on the prevention and treatment of acute respiratory tract infections with traditional Chinese medicine

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025001807
Enrollment
Unknown
Registered
2025-09-24
Start date
2024-12-21
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory infectious diseases

Interventions

Experimental Group:The use of traditional Chinese medicine preparations within the hospital
Control group:Basic treatment

Sponsors

Jiangsu Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for acute respiratory tract infections, including acute upper respiratory tract infections and/or adult community-acquired pneumonia. 2. Applicants must be at least 18 years old, with no gender restrictions. 3. Undergo respiratory pathogen testing within 72 hours. 4. Informed consent and voluntary participation in the examination. The process of obtaining informed consent forms should comply with the provisions of GCP.

Exclusion criteria

Exclusion criteria: 1.The survival time is less than 48 hours. 2. Pregnant and lactating women. 3. Possessing severe primary heart, liver, lung, kidney, blood or serious diseases that affect their survival. 4. Those who are unable to give full informed consent due to intellectual or behavioral disabilities. 5. Suspected or confirmed history of alcohol or drug abuse. 6. Other lesions that, based on the researcher's judgment, may reduce the possibility of enrollment or complicate enrollment, such as frequent changes in the working environment and other situations that are prone to cause loss to follow-up. 7. Allergic constitution, such as those with a history of allergy to two or more drugs or foods; Or those who are known to be allergic to the ingredients of this medicine. 8. Patients who are currently participating in clinical trials of other drugs.

Design outcomes

Primary

MeasureTime frame
Whether it progresses to severe hospitalized respiratory tract infection;

Secondary

MeasureTime frame
WBC;Lymphocyte count;Neutrophil count;CRP;PCT;BUN;Cr;AST;ALT;Chest CT;Nucleic acid or antigen detection of respiratory pathogens;

Countries

China

Contacts

Public ContactTao GUO

Jiangsu Provincial Hospital of Chinese Medicine

saharaicu@126.com13813905939

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026